Welcome to our dedicated page for CeriBell SEC filings (Ticker: CBLL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CeriBell, Inc. filings document the regulatory record of a medical technology company commercializing point-of-care EEG systems for neurological monitoring. Its Form 8-K reports include furnished financial results, FDA clearance events for the Clarity seizure-detection algorithm and other Ceribell System indications, and material agreements related to facility leases and headband supply arrangements.
The company’s proxy materials and governance filings cover annual meeting matters, board composition, committee assignments, director compensation arrangements, indemnification agreements, and related shareholder voting procedures. These disclosures provide formal records of Ceribell’s operating updates, governance structure, contractual obligations, and public-company reporting events.
Ceribell, Inc. director William W. Burke reported an open-market sale of 2,207 shares of Common Stock at a price of $19.84 per share. The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person. After this sale, Burke directly holds 23,022 Ceribell shares, indicating he retains a substantial ongoing equity position in the company.
TPG Rise Clearthought, L.P., an investment entity connected to the reporting group, sold 202,368 shares of Ceribell, Inc. common stock in an open-market transaction at a weighted average price of $20.1203 per share. After this sale on June 26, 2026, TPG Rise Clearthought directly held 3,765,054 Ceribell common shares. The price reflects multiple trades between $19.90 and $20.675. The reporting persons state they may be deemed to beneficially own these securities only to the extent of their respective pecuniary interests and expressly disclaim beneficial ownership beyond that.
Ceribell, Inc. director Joseph Michael Taylor reported an open-market sale of Common Stock. On June 11, 2026, he sold 5,500 shares at $18.41 per share. After this transaction, he continues to hold 61,573 shares of Ceribell common stock directly.
Ceribell, Inc. President and CEO Xingjuan Chao reported a combination of stock option exercises and open-market sales of Common Stock. On June 8, 2026, she exercised options to acquire 25,000 shares of Common Stock at an exercise price of $4.70 per share and sold a total of 39,000 shares of Common Stock in open-market transactions at a weighted average price of approximately $18.33 per share, with individual sale prices ranging from $18.15 to $18.75.
Following these transactions, she held 816,317 shares of Common Stock directly. In addition, 369,088 shares of Common Stock were held indirectly through the ACP 2021 Trust, where she serves as co-trustee and may be deemed to share beneficial ownership, while disclaiming beneficial ownership except to the extent of her pecuniary interest. The stock options exercised carry a $4.70 exercise price and an expiration date of February 16, 2033, and are described as fully vested and currently exercisable. The filing notes that the sale transactions were effected pursuant to a Rule 10b5-1 trading plan, indicating they were executed under a pre-arranged trading program.
CBLL submitted a Rule 144 notice to sell 39,000 shares of Common Stock through Fidelity Brokerage Services LLC. The 39,000 shares arise from three stock option exercises: 8,629 shares (09/25/2024), 5,371 shares (05/15/2025) and 25,000 shares (06/08/2026).
The filing lists recent dispositions by Xingjuan Chao: 39,000 shares sold 04/06/2026 for $717,550.46, 39,000 shares sold 05/05/2026 for $784,000.03, and 6,030 shares sold 05/21/2026 for $108,515.27.
Ceribell, Inc. director Juliet Tammenoms Bakker reported an equity compensation grant and updated holdings. She received 7,838 restricted stock units (RSUs) of common stock at no cost, increasing her direct ownership to 23,284 shares after the award. This is a non‑market, compensation-related acquisition rather than an open-market purchase.
The filing also records 2,475,110 shares of common stock held indirectly through Longitude Venture Partners IV, L.P. Footnotes state that Longitude Capital Partners IV, LLC and its managing members, including Ms. Tammenoms Bakker, may be deemed to share voting and investment power over these securities but each disclaims beneficial ownership except to the extent of their pecuniary interests.
Parvizi Josef reported acquisition or exercise transactions in this Form 4 filing.
Ceribell, Inc. director Josef Parvizi reported an equity award and updated share holdings. He received a grant of 7,838 restricted stock units (RSUs) of common stock at a price of $0.00 per share, increasing his directly held RSUs to 23,284. Footnotes explain that 15,446 of these RSUs were previously reported as indirectly held through the Josef Parvizi Trust but are now held directly.
In addition to the direct RSUs, the filing lists indirect holdings of common stock through three trusts as of the transaction date: 707,206 shares by the Josef Parvizi Trust, 907,911 shares by the Innovation ACP Trust, and 369,088 shares by the ACP 2021 Trust. Parvizi is trustee or co‑trustee of these trusts and may be deemed to have beneficial ownership, but he disclaims beneficial ownership except to the extent of his pecuniary interest.
Rogers Erica J. reported acquisition or exercise transactions in this Form 4 filing.
Ceribell, Inc. director Erica J. Rogers received an award of 7,838 shares of Common Stock in the form of restricted stock units. The RSU grant was recorded at a price of $0.00 per share, bringing her directly held position to 33,054 shares following the award.